###begin article-title 0
###xml 4 10 4 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA5 </italic>
The APOA5 Trp19 allele is associated with metabolic syndrome via its association with plasma triglycerides
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
The goal of the present study was to assess the effect of genetic variability at the APOA5/A4/C3/A1 cluster locus on the risk of metabolic syndrome.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 4 10 4 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA5 </italic>
###xml 20 26 20 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA5 </italic>
###xml 38 44 38 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA4 </italic>
###xml 55 61 55 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOC3 </italic>
###xml 73 79 73 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOC3 </italic>
###xml 88 91 88 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sst</italic>
###xml 168 171 <span type="species:ncbi:9606">men</span>
###xml 176 181 <span type="species:ncbi:9606">women</span>
The APOA5 Ser19Trp, APOA5 -12,238T>C, APOA4 Thr347Ser, APOC3 -482C>T and APOC3 3238C>G (SstI) polymorphisms were analyzed in a representative population sample of 3138 men and women from France, including 932 individuals with metabolic syndrome and 2206 without metabolic syndrome, as defined by the NCEP criteria.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 123 125 123 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 137 143 137 143 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA5 </italic>
###xml 177 179 177 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 191 197 191 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA5 </italic>
###xml 237 239 237 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 251 257 251 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA4 </italic>
###xml 568 574 568 574 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOC3 </italic>
###xml 585 591 585 591 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOC3 </italic>
###xml 690 696 690 696 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA5 </italic>
###xml 709 715 709 715 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA4 </italic>
###xml 766 772 766 772 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA5 </italic>
###xml 851 857 851 857 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA5 </italic>
###xml 872 878 872 878 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA4 </italic>
Compared with homozygotes for the common allele, the odds ratio (OR) [95% CI] for metabolic syndrome was 1.30 [1.03-1.66] (p = 0.03) for APOA5 Trp19 carriers, 0.81 [0.69-0.95] (p = 0.01) for APOA5 -12,238C carriers and 0.84 [0.70-0.99] (p = 0.04) for APOA4 Ser347 carriers. Adjustment for plasma triglycerides, (but not for waist girth, HDL, blood pressure or glycemia - the other components of metabolic syndrome) abolished these associations and suggests that triglyceride levels explain the association with metabolic syndrome. There was no association between the APOC3 -482C>T or APOC3 3238C>G polymorphisms and metabolic syndrome. The decreased risk of metabolic syndrome observed in APOA5 -12,238C and APOA4 Ser347 carriers merely reflected the fact that the APOA5 Trp19 allele was in negative linkage disequilibrium with the common alleles of APOA5 -12,238T>C and APOA4 Thr347Ser polymorphisms.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 4 10 4 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA5 </italic>
The APOA5 Trp19 allele increased susceptibility to metabolic syndrome via its impact on plasma triglyceride levels.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 102 103 102 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 104 105 104 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 561 562 561 562 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 563 564 563 564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 702 703 702 703 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 704 706 704 706 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
Metabolic syndrome is a complex disease characterized by the ustering of several metabolic disorders [1,2]. Excess body weight, insulin resistance, altered plasma lipid levels & glucose homeostasis and increased blood pressure are the principal components of this cluster. Environmental influences (such as low physical activity and an inappropriate diet) play a major role in the development of metabolic syndrome. Furthermore, familial aggregation of metabolic disorders has been reported and suggests a genetic contribution to the etiology of this syndrome [3-5]. Accordingly, it has been reported that genetic variability at several loci is associated with an increased risk of metabolic syndrome [6-12].
###end p 11
###begin p 12
###xml 4 10 4 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA5 </italic>
###xml 108 110 108 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 333 335 333 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 336 338 336 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 341 349 341 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro</italic>
###xml 369 375 369 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA5 </italic>
###xml 485 487 485 487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 570 576 570 576 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA5 </italic>
The APOA5 gene is located on chromosome 11q23 and codes for a 369 amino-acid protein secreted by the liver [13]. In the plasma, APOA5 is bound to triglyceride-rich and high-density lipoproteins. APOA5 reduces plasma triglyceride levels by inhibiting VLDL-triglyceride production and stimulating LPL-mediated triglyceride hydrolysis [14-18]. In vitro, insulin decreases APOA5 promoter activity - suggesting that the hormone may affect triglyceride levels via an interaction with APOA5 [19]. Given its role in triglyceride metabolism and its interaction with insulin, the APOA5 gene is a candidate gene for metabolic syndrome.
###end p 12
###begin p 13
###xml 81 87 81 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA5 </italic>
###xml 327 329 327 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 359 365 359 365 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA5 </italic>
###xml 461 463 461 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 464 466 464 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 467 469 467 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 512 518 512 518 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA5 </italic>
###xml 619 624 619 624 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA4</italic>
###xml 626 632 626 632 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOC3 </italic>
###xml 636 641 636 641 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA1</italic>
###xml 647 653 647 653 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA5 </italic>
###xml 696 698 696 698 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 699 701 699 701 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 783 785 783 785 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 792 798 792 798 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA5 </italic>
###xml 811 817 811 817 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOC3 </italic>
###xml 831 834 831 834 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sst</italic>
Several common single nucleotide polymorphisms (SNPs) have been described in the APOA5 gene locus; these include a T>C substitution at -12,238 (SNP4), a T>C substitution at -1131 (SNP3; rs662799) and a C>G mutation at the first base of codon 19 (rs3135506; c.56C>G) that changes a serine (Ser) residue into a tryptophan (Trp) [20]. An association between the APOA5 Ser19Trp polymorphism and plasma triglycerides has been reported in several population samples [13,20-23]. In contrast, an association between the APOA5 -12,238T>C polymorphism and plasma lipid variables has not been consistently observed. Together with APOA4, APOC3 and APOA1, the APOA5 gene lies within an expanded gene cluster [13,24]. Strong linkage disequilibrium (LD) has been detected for SNPs in this cluster [24]. The APOA5 Ser19Trp and APOC3 3238C>G SNPs (Sst1; rs5128; c.386C>G) both tag common haplotypes in this cluster - haplotypes that may have independent effects on plasma triglycerides.
###end p 13
###begin p 14
The goal of the present study was to assess the relative contribution of SNPs in the APOA5/A4/C3/A1 locus to the risk of metabolic syndrome by analyzing a limited number of representative SNPs within the cluster and a large population-based sample from 3 areas of France.
###end p 14
###begin title 15
Methods
###end title 15
###begin title 16
Subjects
###end title 16
###begin p 17
###xml 618 620 618 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 0 12 <span type="species:ncbi:9606">Participants</span>
###xml 531 543 <span type="species:ncbi:9606">participants</span>
###xml 639 642 <span type="species:ncbi:9606">men</span>
###xml 652 657 <span type="species:ncbi:9606">women</span>
Participants were recruited as part of the WHO-MONICA population survey conducted from 1995 to 1997 in three different parts of France: the Lille Urban Community in northern France (n = 1168), the Bas-Rhin county in eastern France (n = 1117) and the Haute-Garonne county in southern France (n = 1176). The protocol was approved by the appropriate independent ethics committee in each center. Subjects (aged 35-64) were randomly selected from electoral rolls after stratification by town size, gender and age in order to obtain 200 participants for each gender and each 10-year age group (WHO-MONICA Project protocol) [25]. A total of 1746 men and 1715 women completed the recruitment procedure. Subsequently, 323 subjects were excluded due to missing data on at least one criterion for metabolic syndrome.
###end p 17
###begin p 18
###xml 42 54 <span type="species:ncbi:9606">participants</span>
###xml 899 902 <span type="species:ncbi:9606">men</span>
###xml 976 981 <span type="species:ncbi:9606">women</span>
After providing written informed consent, participants filled out a standard questionnaire and physical measurements were taken by a specially trained nurse. The questionnaire covered questions on socioeconomic factors, physical activity, alcohol consumption, smoking status, personal & family medical history and current medications taken (if any). The level of leisure-time physical activity during was categorized as follows: none, light (light physical activity almost every week), intense (at least 20 minutes of intense physical activity more than once a week). In terms of smoking exposure, subjects were categorized as never-smokers, former smokers and current smokers (i.e. subjects reporting at least one cigarette per day). Total alcohol intake was expressed as the sum of ml alcohol per week from wine, beer, cider and spirits. Alcohol consumption was categorized in 4 Q1-Q4 classes for men [</=100 ml/week; 100-250 ml/week; 250-500 ml/week; >500 ml/week] and for women [0 ml/week; 0-60 ml/week; 60-190 ml/week; > 190 ml/week]. Educational level was assessed by counting the number of years of schooling and classifying the values into 3 categories: primary, secondary/technical and university. Anthropometric measurements included body weight (rounded to the nearest even decimal), waist girth (at a level midway between the lower rib margin and the iliac crest, to the nearest 0.5 cm) and were performed on subjects in light clothing without shoes. Body mass index was calculated according to the Quetelet equation.
###end p 18
###begin p 19
###xml 254 256 248 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 738 740 722 724 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 152 155 <span type="species:ncbi:9606">men</span>
###xml 172 177 <span type="species:ncbi:9606">women</span>
###xml 354 357 <span type="species:ncbi:9606">men</span>
###xml 374 379 <span type="species:ncbi:9606">women</span>
###xml 470 473 <span type="species:ncbi:9606">men</span>
###xml 493 498 <span type="species:ncbi:9606">women</span>
###xml 954 957 <span type="species:ncbi:9606">men</span>
###xml 962 967 <span type="species:ncbi:9606">women</span>
Diabetic subjects were identified by fasting glycemia >/=126 mg/dl or antidiabetic treatment. Abdominal obesity was defined by waist girth >/=102 cm in men and >/=88 cm in women. Metabolic syndrome was defined (according to the NCEP III recommendations [26]) by the presence of at least 3 or more of the following abnormalities: waist girth >/=102 cm in men and >/=88 cm in women, triglycerides >/= 1.7 mmol/L or treatment with fibrates, HDL-cholesterol <1.04 mmol/L in men and <1.29 mol/L in women, blood pressure >/= 130/85 mm Hg or treatment with blood pressure-lowering medications and fasting glucose >/= 6.1 mmol/L or type 2 diabetes. Additional analyses were performed using the International Diabetes Federation (IDF) definition [27] of metabolic syndrome. This definition is based on the same criteria as the NCEP definition except that (i) increased waist girth is a mandatory criteria and (ii) the waist cut-offs are 94 and 80 cm for European men and women, respectively.
###end p 19
###begin title 20
Laboratory methods
###end title 20
###begin p 21
###xml 646 652 646 652 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA5 </italic>
###xml 703 707 703 705 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 965 971 963 969 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOC3 </italic>
###xml 980 983 978 981 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sst</italic>
###xml 1242 1248 1240 1246 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOC3 </italic>
###xml 1315 1319 1313 1315 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 1555 1561 1551 1557 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA4 </italic>
###xml 1622 1624 1618 1620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 1631 1637 1627 1633 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA5 </italic>
###xml 1847 1850 1843 1846 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hae</italic>
###xml 1891 1894 1887 1890 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hae</italic>
A 20 mL blood sample was drawn into a disodium EDTA tube (after the subjects had fasted for at least 10 hours), stored at room temperature and centrifuged within 4 hours. All measurements were performed in a central laboratory (Purpan Hospital, Toulouse, France). Cholesterol and triglyceride levels were measured using enzyme assays (Boehringer Mannheim, Mannheim, Germany). High density lipoprotein (HDL) cholesterol was measured after sodium phosphotungstate/magnesium chloride precipitation (Boehringer Mannheim, Mannheim, Germany). Glucose was measured using the standard glucose hexokinase method (DuPont Dimension, Brussels, Belgium). The APOA5 Ser19Trp polymorphism was assessed in an Amplifluor(R) genotyping system using the following probes: APOA5-F1: 5' GAAGGTGACCAAGTTCATGCTTCCCTCTCCACAGCGTTTTC-3'; APOA5-F2: 5'-GAAGGTCGGAGTCAACGGATTTCCCTCTCCACAGCGTTTTG-3' and APOA5-R: 5'-TGAAGTAGTCCCAGAAGCCTTT-3'. In the sample, 1.6% was undetermined. Likewise, the APOC3 3238C>G (SstI) polymorphism was assessed using the following probes: APOC3-F1: 5'-GAAGGTCGGAGTCAACGGATTACCTGCCTATCCATCCTGCC-3', APOC3-F2: 5'-GAAGGTGACCAAGTTCATGCTACCTGCCTATCCATCCTGCG-3' and APOC3-R: 5'-GCACTGAGAATACTGTCCCTTT-3'. In the sample, 3.5% was undetermined. The APOC3 -482C>T (rs2854117) polymorphism was also assessed in an Amplifluor(R) system using the following probes: APOC3-F1: 5'-GAAGGTGACCAAGTTCATGCTAGTAAAGGCACAGAAGACCG-3', APOC3-F2: 5'-GAAGGTCGGAGTCAACGGATTGAGTAAAGGCACAGAAGACCA-3' and APOC3-R: 5'-TGAAACCCAGAGATGGAGGT-3'. In the sample, 3.8% was undetermined. The APOA4 Thr347Ser polymorphism was assessed as previously described [28]. The APOA5 -12,238T>C polymorphism was genotyped with an RFLP-based method using the following primers: forward 5'-GTGCCTGTCACCACCGTTTG-3' and reverse 5'-ATGCATTAGCCTCTGCTGTTC-3' (generating a forced restriction site for HaeIII). The 162 bp PCR fragment was cut by HaeIII into 2 fragments (141 and 21 bp) for the T allele, whereas a single uncut product resulted for the C allele. Products were resolved on 3% agarose gels. For each method, around 10% of the samples were genotyped twice and no discordant genotypes were observed.
###end p 21
###begin title 22
Statistical analyses
###end title 22
###begin p 23
###xml 1035 1037 1035 1037 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 1111 1115 1111 1115 <sub xmlns:xlink="http://www.w3.org/1999/xlink">max </sub>
###xml 1121 1125 1121 1125 <sub xmlns:xlink="http://www.w3.org/1999/xlink">min </sub>
###xml 1126 1128 1126 1128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 1274 1276 1274 1276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 1277 1279 1277 1279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
General linear models (GLM) and chi-square tests were used to compare the clinical and biological characteristics of subjects with or without metabolic syndrome. Furthermore, GLM and Chi-square tests were used to compare centers in terms of mean values and the distributions of variables and genotypes, respectively. A GLM adjusted for age, gender and center was used to compare genotype groups in terms of metabolic syndrome criteria. Subjects receiving a treatment that may have affected the level of the variable were excluded from these analyses. Chi-square tests and logistic regression analyses were used to test the association between the various genotypes and metabolic syndrome. For logistic regression analyses, carriers of at least one minor allele were compared with subjects who were homozygous for the frequent allele (dominant model), while adjusting for age, gender and center. The threshold for statistical significance was set to 5%. Linkage disequilibrium between loci was tested using a log-likelihood-ratio test [29]. Disequilibrium was expressed in terms of normalized difference D' = D/Dmax or D/Dmin [30]. Haplotype frequencies were estimated using a stochastic version of the expectation-maximization algorithm, as implemented in Thesias software [31,32]. Differences in haplotype frequencies when comparing groups of subjects with or without metabolic syndrome were examined using a log-likelihood ratio statistic test, which was computed from the haplotype frequency log-likelihoods for each of the two groups estimated in Thesias.
###end p 23
###begin title 24
Results
###end title 24
###begin p 25
###xml 6 7 6 7 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
Table 1 shows the biological and clinical characteristics of the subjects with (n = 932) and without (n = 2206) metabolic syndrome as defined by NCEP III. As expected, body mass index, waist girth, triglyceridemia, cholesterolemia, glycemia, systolic and diastolic blood pressure were higher and HDL-cholesterol levels were lower in subjects with metabolic syndrome than in subjects without metabolic syndrome (all p < 0.0001). Subjects with metabolic syndrome were less physically active and had spent less time in education than those without metabolic syndrome. The proportion of smokers was lower in the metabolic syndrome group.
###end p 25
###begin p 26
Anthropometric, clinical and biological characteristics of subjects with or without metabolic syndrome
###end p 26
###begin p 27
Values are means+/- SD or n (%).
###end p 27
###begin p 28
BMI : body mass index ; HDL : high density lipoprotein ; SBP/DBP : systolic and diastolic blood pressure ; alcohol intake is in quartiles.
###end p 28
###begin p 29
###xml 4 10 4 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA5 </italic>
###xml 19 25 19 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA5 </italic>
###xml 37 43 37 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA4 </italic>
###xml 54 60 54 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOC3 </italic>
###xml 72 78 72 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOC3 </italic>
###xml 151 152 151 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 278 282 278 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA</italic>
###xml 288 294 288 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA4 </italic>
###xml 409 411 407 409 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 459 465 457 463 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA5 </italic>
###xml 480 486 478 484 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA4 </italic>
###xml 542 548 540 546 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA5 </italic>
###xml 567 573 565 571 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOC3 </italic>
###xml 653 659 651 657 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA4 </italic>
###xml 721 727 719 725 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOC3 </italic>
###xml 790 796 788 794 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOC3 </italic>
The APOA5 Ser19Trp,APOA5 -12,238T>C, APOA4 Thr347Ser, APOC3 -482C>T and APOC3 3238C>G genotypes did not deviate from Hardy-Weinberg equilibrium. Table 2 shows the linkage disequilibrium matrix in subjects without metabolic syndrome. Overall, the |D'| varied from 0.29 to 1. The APOA5 and APOA4 SNPs were in the same haplotype block (|D'|>/=0.85); however, due to differences in minor allele frequencies, the r2 values were almost nil. Within this block, both APOA5 -12,238T>C and APOA4 Thr347Ser SNPs were in negative disequilibrium with the APOA5 Ser19Trp SNP. Both APOC3 SNPs were within the same linkage disequilibrium block (D' = 0.91). Lastly, the APOA4 Thr347Ser SNP was in negative linkage disequilibrium with the APOC3 3238C>G SNP (D' = -0.92) and thus showed some overlap with the APOC3 haplotype block.
###end p 29
###begin p 30
###xml 8 10 8 10 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
D' and r2 values for linkage disequilibrium among polymorphisms in subjects without metabolic syndrome
###end p 30
###begin p 31
###xml 25 27 25 27 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
D' upper right corner ; r2 lower left corner
###end p 31
###begin p 32
###xml 6 7 6 7 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 305 311 305 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA5 </italic>
###xml 362 368 362 368 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOC3 </italic>
###xml 409 415 409 415 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOC3 </italic>
###xml 528 534 528 534 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA5 </italic>
###xml 586 592 586 592 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA4 </italic>
###xml 727 733 727 733 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA5 </italic>
###xml 875 881 875 881 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA5 </italic>
###xml 968 974 968 974 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA4 </italic>
Table 3 shows the metabolic syndrome-related anthropometric, biological and clinical parameters in subjects without metabolic syndrome and as a function of the 5 polymorphisms. Multivariate analyses (adjusted for age, gender and center) revealed that mean triglyceride levels were significantly higher in APOA5 Trp19 (p < 0.0001; p < 0.0001 in a dominant model),APOC3 -482T (p = 0.04 in a dominant model) and APOC3 3238G (p < 0.0001; p < 0.0001 in a dominant model) allele carriers. Conversely, mean triglycerides were lower in APOA5 -12,238C (p < 0.01; p = 0.003 in a dominant model), APOA4 Ser347 (p = 0.04 in a dominant model) allele carriers than in non-carriers. The mean HDL-cholesterol value was significantly higher in APOA5 -12,238C (p = 0.04; p = 0.02 in a dominant model) allele carriers than in non-carriers. Systolic and diastolic blood pressures were higher in APOA5 Trp19 carriers (p = 0.03 in a dominant model) and systolic blood pressure was lower in APOA4 Ser347 carriers (p = 0.03 in a dominant model). There were no other statistically significant associations for any of the SNPs. Further adjustment for physical activity, alcohol consumption, smoking habits and educational level yielded similar results (data not shown). These associations were similarly observed in all three centers (i.e. there was no significant interaction with geographical area).
###end p 32
###begin p 33
Mean levels of metabolic syndrome-related anthropometric, biological and clinical parameters in subjects without metabolic syndrome according to the 5 polymorphisms
###end p 33
###begin p 34
###xml 46 48 46 48 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a </sup>
###xml 53 55 53 55 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b </sup>
###xml 113 114 113 114 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 309 311 309 311 <sup xmlns:xlink="http://www.w3.org/1999/xlink">d </sup>
###xml 326 328 326 328 <sup xmlns:xlink="http://www.w3.org/1999/xlink">e </sup>
###xml 358 360 358 360 <sup xmlns:xlink="http://www.w3.org/1999/xlink">f </sup>
p values ajusted on age, gender and center ; pa and pb values for a dominant and recessive models, respectively; canalyses on log-transformed data ; BMI : body mass index ; TG : triglycerides ; HDL : high density lipoprotein ; SBP/DBP : systolic and diastolic blood pressure ; Exclusion of subjects treated : d with fibrates, e oral antidiabetic or insulin, f BP lowering therapy.
###end p 34
###begin p 35
###xml 208 214 208 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA5 </italic>
###xml 243 249 243 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA4 </italic>
###xml 271 277 271 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOC3 </italic>
###xml 448 449 448 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 553 555 553 555 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-8</sup>
###xml 719 720 719 720 <underline xmlns:xlink="http://www.w3.org/1999/xlink">G</underline>
###xml 780 786 780 786 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA5 </italic>
###xml 889 891 889 891 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6</sup>
###xml 918 920 918 920 <underline xmlns:xlink="http://www.w3.org/1999/xlink">TG</underline>
###xml 939 945 939 945 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOC3 </italic>
###xml 949 950 949 950 <underline xmlns:xlink="http://www.w3.org/1999/xlink">T</underline>
###xml 959 960 959 960 <underline xmlns:xlink="http://www.w3.org/1999/xlink">G</underline>
###xml 1110 1112 1110 1112 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6</sup>
In order to assess the contribution of the genetic variability to plasma triglyceride levels, haplotype analyses were performed in subjects without metabolic syndrome using the 5 SNPs in the following order: APOA5 (Ser(C)19Trp(G), -12,238T>C),APOA4 (Thr(A)347Ser(T)) and APOC3 (-482C>T, 3238C>G). Eight haplotypes had an estimated frequency of above 1% (accounting for more than 97% of the existing haplotypes) and were used in the analyses (Table 4). The overall association between haplotypes and triglyceride levels was highly significant (p < 4 x 10-8). By reference to the most common haplotype (CTACC; estimated frequency: 0.45), two haplotypes were significantly associated with raised plasma triglycerides. The GTACC haplotype (estimated frequency: 0.05) that carried the APOA5 Trp19 allele on the common background was associated with a 30% increase in triglyceride levels (p < 10-6). The other haplotype (CTATG) carried both the APOC3 -482T and 3238G minor alleles on the common genetic background (estimated frequency: 0.08) and was also associated with a 30% increase in triglyceride levels (p < 10-6).
###end p 35
###begin p 36
Haplotype frequencies and delta values of mean triglycerides in subjects without metabolic syndrome
###end p 36
###begin p 37
###xml 78 84 78 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA5 </italic>
###xml 113 119 113 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA4 </italic>
###xml 141 147 141 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOC3 </italic>
Only haplotypes with a frequency above 1% are represented. Order of the SNPS: APOA5 (Ser(C)19Trp(G), 12,238T>C), APOA4 (Thr(A)347Ser(T)) and APOC3 (-482C>T, 3238C>G). p values adjusted for age, gender and center.
###end p 37
###begin p 38
###xml 6 7 6 7 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T5">5</xref>
###xml 179 185 179 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA5 </italic>
###xml 212 218 212 218 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA4 </italic>
###xml 455 456 455 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T6">6</xref>
###xml 462 468 462 468 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA5 </italic>
###xml 560 566 560 566 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA5 </italic>
###xml 594 600 594 600 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA4 </italic>
###xml 914 920 914 920 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOC3 </italic>
Table 5 shows the genotype distribution of the 5 SNPs in subjects with or without metabolic syndrome. The two groups of subjects differed in terms of the genotype distribution of APOA5 -12,238T>C (p = 0.026) and APOA4 Thr347Ser (p = 0.034) SNPs. The adjusted odds ratio (OR) and 95% confidence interval (CI) for metabolic syndrome in carriers of at least one minor allele (compared with subjects homozygous for the frequent allele) are presented in Table 6. The APOA5 Trp19 allele conferred an increased risk of metabolic syndrome (p = 0.03). In contrast, the APOA5 -12,238C (p = 0.01) and the APOA4 Ser347 (p = 0.04) alleles were associated with a lower risk of metabolic syndrome. Adjustment for plasma triglycerides but not for other metabolic syndrome criteria (i.e. waist girth, HDL, glycemia and systolic blood pressure) abolished these associations. Lastly, there was no significant association between the APOC3 -482C>T and 3238C>G polymorphisms and metabolic syndrome. Using the IDF criteria for metabolic syndrome, the ORs [95%CI] for metabolic syndrome were similar in magnitude (data not shown).
###end p 38
###begin p 39
Genotype distributions in subjects with or without metabolic syndrome (MS)
###end p 39
###begin p 40
Values are number (%).
###end p 40
###begin p 41
Odds ratios for metabolic syndrome in carriers of the minor allele
###end p 41
###begin p 42
The reference groups were homozygous subjects for the frequent allele. Odds ratios and p values adjusted for age, gender and center.
###end p 42
###begin p 43
###xml 339 340 339 340 <underline xmlns:xlink="http://www.w3.org/1999/xlink">G</underline>
###xml 369 375 369 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA5 </italic>
###xml 510 513 510 513 <underline xmlns:xlink="http://www.w3.org/1999/xlink">CTT</underline>
###xml 529 535 529 535 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA5 </italic>
###xml 541 542 541 542 <underline xmlns:xlink="http://www.w3.org/1999/xlink">C</underline>
###xml 548 554 548 554 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA4 </italic>
###xml 569 575 569 575 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOC3 </italic>
###xml 579 580 579 580 <underline xmlns:xlink="http://www.w3.org/1999/xlink">T</underline>
###xml 675 681 675 681 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOC3 </italic>
###xml 685 691 685 691 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA5 </italic>
###xml 839 844 839 844 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APO5 </italic>
###xml 871 877 871 877 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA4 </italic>
###xml 1027 1028 1027 1028 <underline xmlns:xlink="http://www.w3.org/1999/xlink">G</underline>
###xml 1067 1069 1067 1069 <underline xmlns:xlink="http://www.w3.org/1999/xlink">CT</underline>
###xml 1345 1351 1345 1351 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOC3 </italic>
Haplotype analyses using the 5 SNPs were performed to assess the relationship with metabolic syndrome. The overall association between the haplotypes and metabolic syndrome was statistically significant (p = 0.011). With respect to the most common haplotype (CTACC), 2 haplotypes were significantly associated with metabolic syndrome. The GTACC haplotype (carrying the APOA5 Trp19 allele on the common background) was associated with a 33% greater risk of metabolic syndrome (p < 0.005). The other haplotype (CCTTC, carrying the APOA5 12,238C, the APOA4 Ser347 and the APOC3 -482T alleles) was associated with a 26% reduction in metabolic syndrome risk (p = 0.03). Since the APOC3 and APOA5 SNPs are in different haplotype blocks, the association with metabolic syndrome was tested for the two blocks independently. Using only the SNPs of APO5 (Ser19Trp, -12,238T>C) and APOA4 Thr347Ser, we found 4 possible haplotypes with a frequency of above 1%. When compared with the common haplotype (CTA; estimated frequency: 0.58), the GTA (estimated frequency 0.05) and the CCT (estimated frequency 0.19) haplotypes were respectively associated with a 33% greater risk (p < 0.02) and a 17% lower risk (p = 0.034) of metabolic syndrome. Both associations disappeared after adjustment for triglyceride levels. In contrast, haplotype analyses with the two APOC3 SNPs did not reveal any significant association with metabolic syndrome.
###end p 43
###begin title 44
Discussion
###end title 44
###begin p 45
###xml 162 168 162 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA5 </italic>
###xml 358 364 358 364 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA5 </italic>
###xml 377 383 377 383 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA4 </italic>
###xml 519 525 519 525 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA5 </italic>
###xml 556 562 556 562 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOC3 </italic>
The goal of the present study was to assess the contribution of SNPs in the APOA5/A4/C3/A1 cluster to the risk of metabolic syndrome. Our results showed that the APOA5 Trp19 allele was associated with an increased risk of metabolic syndrome and that this association could possibly be explained by an increase in plasma triglyceride levels. Furthermore, the APOA5 -12,238C and APOA4 Ser347 alleles were associated with a lower risk of metabolic syndrome - possibly due to their negative linkage disequilibrium with the APOA5 Trp19 allele. In contrast, the APOC3 -482C>T and 3238C>G SNPs did not appear to be related to metabolic syndrome in this French sample.
###end p 45
###begin p 46
###xml 165 171 165 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA5 </italic>
###xml 201 207 201 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOC3 </italic>
###xml 217 223 217 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOC3 </italic>
###xml 495 501 495 501 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA5 </italic>
###xml 511 517 511 517 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOC3 </italic>
###xml 532 534 532 534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 587 593 587 593 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA5 </italic>
###xml 603 609 603 609 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA4 </italic>
###xml 941 943 941 943 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 1001 1003 1001 1003 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
All 5 SNPs of the cluster tested in this study were associated with triglyceride levels. Compared with the most common haplotype, haplotypes that carried either the APOA5 Trp19 allele only or both the APOC3 -482T and APOC3 3238G alleles were found to be independently associated with elevated triglycerides. These results are consistent with earlier studies in different population samples that reported similar linkage disequilibrium patterns and associations with triglycerides (driven by the APOA5 Trp19 and APOC3 -482T alleles [20]). In addition to elevated triglyceride levels, the APOA5 Trp19 and APOA4 Thr347 alleles were associated with higher blood pressure. A direct effect of APOA5 or APOA4 on blood pressure regulation is unlikely. In contrast, there is experimental evidence to suggest that chronic hypertriglyceridemia leads to endothelium dysfunction, which is associated with an impaired response to vasodilator stimulation [33] and a subsequent decrease in nitric oxide availability [34] - phenomena which may result in increased blood pressure.
###end p 46
###begin p 47
###xml 4 10 4 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA5 </italic>
###xml 84 90 84 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA5 </italic>
###xml 103 109 103 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA4 </italic>
###xml 187 193 187 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA5 </italic>
###xml 222 223 222 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 224 226 224 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 371 377 371 377 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA5 </italic>
###xml 390 396 390 396 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA4 </italic>
###xml 503 509 503 509 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA5 </italic>
###xml 645 651 645 651 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA5 </italic>
###xml 897 903 897 903 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA5 </italic>
###xml 906 912 906 912 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA4 </italic>
###xml 981 987 981 987 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA5 </italic>
###xml 991 997 991 997 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA4 </italic>
The APOA5 Trp19 allele increased the odds ratio for metabolic syndrome, whereas the APOA5 -12,238C and APOA4 Ser347 alleles decreased it. Other studies have reported associations between APOA5 SNPs and metabolic syndrome [8-12]. Our results extend this observation to a different European population sample. The reduced risk of metabolic syndrome observed in carriers of APOA5 -12,238C and APOA4 Ser347 alleles merely reflected the negative linkage disequilibrium existing between these alleles and the APOA5 Trp19 allele. Several lines of evidence suggest that the association with metabolic syndrome is mediated by triglycerides. Firstly, the APOA5 Trp19 allele is associated strongly and independently with triglyceride levels but far less so with blood pressure. Secondly, adjustment for triglycerides (but not for other metabolic syndrome-related criteria) abolished the associations between APOA5 or APOA4 SNPs and the risk of metabolic syndrome. Overall, this suggests that APOA5 and APOA4 genetic variability affected susceptibility to metabolic syndrome.
###end p 47
###begin p 48
###xml 17 23 17 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOC3 </italic>
###xml 35 41 35 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOC3 </italic>
###xml 258 264 258 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA5 </italic>
###xml 418 424 418 424 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA5 </italic>
###xml 442 448 442 448 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOC3 </italic>
###xml 657 663 657 663 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA5 </italic>
###xml 706 712 706 712 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOC3 </italic>
In contrast, the APOC3 -482C>T and APOC3 3238C>G SNPs did not significantly affect the risk of metabolic syndrome in this sample of French origin, despite significant association with triglyceride level. These SNPs do not belong to the same haplotype as the APOA5 Ser19Trp SNP and have an independent effect on plasma triglycerides, which may explain the difference vis-a-vis APOA5. Furthermore and in contrast to the APOA5 Ser19Trp SNP, the APOC3 SNPs were not associated with another component of metabolic syndrome (such as blood pressure) which could explain this difference. Lastly, the prevalence of hypertriglyceridemia was higher in carriers of the APOA5 Trp19 allele (35%) than in carriers of the APOC3 -482T (23%) or APOC3 3238G (22%) alleles and thus increased the probability of fulfilling the definition of metabolic syndrome.
###end p 48
###begin p 49
###xml 1319 1325 1312 1318 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA5 </italic>
###xml 1354 1355 1347 1348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 1356 1358 1349 1351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 167 175 <span type="species:ncbi:9606">patients</span>
This study has both strengths and limitations. It was performed on a representative sample of the French population and therefore avoided potential selection bias for patients and controls. There were more than 900 subjects with metabolic syndrome, which yields enough statistical power to detect an OR of 1.3 for an allele frequency of 10% at alpha = 0.05 and beta = 90%. Despite this large number of subjects with metabolic syndrome, the statistical power of the study was still not sufficient to account for possible type 1 error due to multiple testing. Therefore, corrections for multiple testing were not applied in the present analysis. In our sample, subjects without metabolic syndrome were, on average, 5 years younger than those with metabolic syndrome. Since metabolic syndrome prevalence increases with age, this may possibly confound (underestimate) the odds ratio associated with the SNPs. However, all our analyses were adjusted for age, in order to account for a possible impact of the latter parameter on the association. Since only a few SNPs per gene were studied, we cannot completely rule out the possibility that other SNPs in different gene loci or specific haplotypes can also contribute to genetic susceptibility to metabolic syndrome. Indeed, other studies have reported associations between APOA5 SNPs and metabolic syndrome [8-12]. Lastly, we used the NCEP working definition of metabolic syndrome; however, additional analyses using the IDF consensus definition generated very similar conclusions and suggested that choice of the definition of metabolic syndrome does not affect the relationship between metabolic syndrome and the SNPs studied here.
###end p 49
###begin title 50
Conclusion
###end title 50
###begin p 51
###xml 432 438 432 438 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA5 </italic>
Over the past decades, genetic variability in the APOA5/A4/C3/A1 cluster has been associated (to varying extents) with variability in plasma lipid, apolipoprotein and lipoprotein levels and with an increased risk of cardiovascular disease. The results of the present study further suggest that the association of SNPs in this cluster with metabolic syndrome may be explained by the propensity of plasma triglycerides to increase in APOA5 Trp19 allele carriers.
###end p 51
###begin title 52
Competing interests
###end title 52
###begin p 53
The authors declare that they have no competing interests.
###end p 53
###begin title 54
Authors' contributions
###end title 54
###begin p 55
DC, AW, PD, JBR, DA, AB, JF and PA participated in the design and coordination of the study. JD and AM carried out the molecular genetic studies, performed the statistical analyses, wrote the paper. All authors read and approved the final manuscript.
###end p 55
###begin title 56
Pre-publication history
###end title 56
###begin p 57
The pre-publication history for this paper can be accessed here:
###end p 57
###begin p 58

###end p 58
###begin title 59
Acknowledgements
###end title 59
###begin p 60
These population surveys were supported by unrestricted grants from the Conseil Regional du Nord-Pas de Calais, ONIVINS, Parke-Davies Laboratory, the Mutuelle Generale de l'Education Nationale (MGEN), Groupe Fournier, the Reseau National de Sante Publique, the Direction Generale de la Sante, the Institut National de la Sante Et de la Recherche Medicale (INSERM), the Institut Pasteur de Lille, the Unite d'Evaluation du Centre Hospitalier et Universitaire de Lille, the Centre d'Examen de Sante de Strasbourg, the CPAM de Selestat and the Federation Regionale de Cardiologie d'Alsace. "La Fondation de France" is also acknowledged.
###end p 60
###begin article-title 61
###xml 52 57 <span type="species:ncbi:9606">human</span>
Banting lecture 1988. Role of insulin resistance in human disease
###end article-title 61
###begin article-title 62
Metabolic syndrome X: A review
###end article-title 62
###begin article-title 63
Genetic analysis of the IRS. Pleiotropic effects of genes influencing insulin levels on lipoprotein and obesity measures
###end article-title 63
###begin article-title 64
Genetic and environmental architecture of the features of the insulin-resistance syndrome
###end article-title 64
###begin article-title 65
The association of cardiovascular risk factor clustering related to insulin resistance syndrome (Syndrome X) between young parents and their offspring: the Bogalusa Heart Study
###end article-title 65
###begin article-title 66
###xml 121 124 <span type="species:ncbi:9606">men</span>
The Gly16-->Arg16 and Gln27-->Glu27 polymorphisms of beta2-adrenergic receptor are associated with metabolic syndrome in men
###end article-title 66
###begin article-title 67
###xml 117 120 <span type="species:ncbi:9606">men</span>
###xml 125 130 <span type="species:ncbi:9606">women</span>
Association between peroxisome proliferator-activated receptor gamma haplotypes and the metabolic syndrome in French men and women
###end article-title 67
###begin article-title 68
Prediction of genetic risk for metabolic syndrome
###end article-title 68
###begin article-title 69
###xml 121 127 <span type="species:ncbi:9606">people</span>
Genetic risk for metabolic syndrome: examination of candidate gene polymorphisms related to lipid metabolism in Japanese people
###end article-title 69
###begin article-title 70
APOA5 variants and metabolic syndrome in Caucasians
###end article-title 70
###begin article-title 71
Apolipoprotein A5 IVS3+476A allelic variant associates with increased trigliceride levels and confers risk for development of metabolic syndrome in Hungarians
###end article-title 71
###begin article-title 72
Apolipoprotein A5 T-1131C variant confers risk for metabolic syndrome
###end article-title 72
###begin article-title 73
###xml 47 53 <span type="species:ncbi:9606">humans</span>
###xml 58 62 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing
###end article-title 73
###begin article-title 74
###xml 100 104 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
Analysis of apolipoprotein A5, c3, and plasma triglyceride concentrations in genetically engineered mice
###end article-title 74
###begin article-title 75
###xml 38 42 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 54 59 <span type="species:ncbi:9606">human</span>
Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5
###end article-title 75
###begin article-title 76
ApoAV reduces plasma triglycerides by inhibiting very low density lipoprotein-triglyceride (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis
###end article-title 76
###begin article-title 77
The role and mode of action of apolipoproteins CIII and AV: synergistic actors in triglyceride metabolism?
###end article-title 77
###begin article-title 78
Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan-bound lipoprotein lipase
###end article-title 78
###begin article-title 79
Insulin-mediated down-regulation of apolipoprotein A5 gene expression through the phosphatidylinositol 3-kinase pathway: role of upstream stimulatory factor
###end article-title 79
###begin article-title 80
###xml 55 60 <span type="species:ncbi:9606">human</span>
Two independent apolipoprotein A5 haplotypes influence human plasma triglyceride levels
###end article-title 80
###begin article-title 81
Apolipoprotein A5 and triglyceridemia. Focus on the effects of the common variants
###end article-title 81
###begin article-title 82
Triglyceride associated polymorphisms of the APOA5 gene have very different allele frequencies in Pune, India compared to Europeans
###end article-title 82
###begin article-title 83
The APOA1/C3/A4/A5 gene cluster, lipid metabolism and cardiovascular disease risk
###end article-title 83
###begin article-title 84
Relative contribution of variation within the APOC3/A4/A5 gene cluster in determining plasma triglycerides
###end article-title 84
###begin article-title 85
The World Health Organization MONICA Project (monitoring trends and determinants in cardiovascular disease): a major international collaboration. WHO MONICA Project Principal Investigators
###end article-title 85
###begin article-title 86
Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Executive summary
###end article-title 86
###begin article-title 87
The metabolic syndrome - a new worldwide definition
###end article-title 87
###begin article-title 88
Genetic polymorphisms of the apolipoprotein A-IV in a Greek population and their relation to plasma lipid and lipoprotein levels
###end article-title 88
###begin article-title 89
Testing for linkage disequilibrium in genotypic data using the Expectation-Maximization algorithm
###end article-title 89
###begin article-title 90
The interaction of selection and linkage. I. General considerations; heterotic models
###end article-title 90
###begin article-title 91
Specific haplotypes of the P-selectin gene are associated with myocardial infarction
###end article-title 91
###begin article-title 92
A new algorithm for haplotype-based association analysis: the Stochastic-EM algorithm
###end article-title 92
###begin article-title 93
Waist circumference and waist-to-hip ratio as predictors of cardiovascular events: meta-regression analysis of prospective studies
###end article-title 93
###begin article-title 94
###xml 87 91 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
Chronic selective hypertriglyceridemia impairs endothelium-dependent vasodilatation in rats
###end article-title 94

